ASH 2024 – John Seymour
John Seymour elucidates the promising outcomes of BTK degraders in hematological malignancies, as for example demonstrated in the CaDAnCe-101 trial, and reflects on their future role in treatment strategies. He delves into the pros and cons of fixed-duration versus continuous therapy in CLL and highlights the clinical significance of clonal hematopoiesis in patients with CLL.
